Cargando…
Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis
Clostridium difficile infection (CDI) is a leading cause of healthcare-associated infections, accounting for significant disease burden and mortality. The clinical spectrum of C. difficile ranges from asymptomatic colonization to toxic megacolon and fulminant colitis. CDI is characterized by new ons...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116462/ https://www.ncbi.nlm.nih.gov/pubmed/33770398 http://dx.doi.org/10.1007/s40121-021-00417-7 |
_version_ | 1783691399338655744 |
---|---|
author | Lee, Helen S. Plechot, Kamryn Gohil, Shruti Le, Jennifer |
author_facet | Lee, Helen S. Plechot, Kamryn Gohil, Shruti Le, Jennifer |
author_sort | Lee, Helen S. |
collection | PubMed |
description | Clostridium difficile infection (CDI) is a leading cause of healthcare-associated infections, accounting for significant disease burden and mortality. The clinical spectrum of C. difficile ranges from asymptomatic colonization to toxic megacolon and fulminant colitis. CDI is characterized by new onset of ≥ 3 unformed stools in 24 h and is confirmed by laboratory test for the presence of toxigenic C. difficile. Currently, laboratory tests to diagnose CDI include toxigenic culture, glutamate dehydrogenase (GDH), nucleic acid amplification test (NAAT), and toxins A/B enzyme immunoassay (EIA). The sensitivities of these tests are variable with toxin EIA ranging from 53 to 60% and with NAAT at about 95%. Overall, the specificity is > 90% for these methods. However, the positive predictive value (PPV) depends on the disease prevalence with lower CDI rates associated with lower PPVs. Notably, the widespread use of the highly sensitive NAAT and its relatively lower clinical specificity have led to overdiagnosis of C. difficile by identifying carriers when NAAT is used as the sole diagnostic method. Overdiagnosis of C. difficile has resulted in unwarranted treatment, possibly attributing to resistance to metronidazole and vancomycin, increased risk for overgrowth of vancomycin-resistant enterococci strains in stool specimens, and increased hospitalization thereby impacting patient safety and healthcare costs. Strategies to optimize the clinical sensitivity and specificity of current laboratory tests are critical to differentiate the clinical CDI from colonization. To achieve high diagnostic yield, if preagreed institutional criteria for stool submission are not used, a multistep approach to CDI diagnosis is recommended, such as either GDH or NAAT followed by toxins A/B EIA in conjunction with laboratory stewardship by evaluating C. difficile test orders for appropriateness and providing feedback. Furthermore, antimicrobial stewardship, along with provider education on appropriate testing for C. difficile, is vital to differentiate CDI from colonization. |
format | Online Article Text |
id | pubmed-8116462 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-81164622021-05-14 Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis Lee, Helen S. Plechot, Kamryn Gohil, Shruti Le, Jennifer Infect Dis Ther Review Clostridium difficile infection (CDI) is a leading cause of healthcare-associated infections, accounting for significant disease burden and mortality. The clinical spectrum of C. difficile ranges from asymptomatic colonization to toxic megacolon and fulminant colitis. CDI is characterized by new onset of ≥ 3 unformed stools in 24 h and is confirmed by laboratory test for the presence of toxigenic C. difficile. Currently, laboratory tests to diagnose CDI include toxigenic culture, glutamate dehydrogenase (GDH), nucleic acid amplification test (NAAT), and toxins A/B enzyme immunoassay (EIA). The sensitivities of these tests are variable with toxin EIA ranging from 53 to 60% and with NAAT at about 95%. Overall, the specificity is > 90% for these methods. However, the positive predictive value (PPV) depends on the disease prevalence with lower CDI rates associated with lower PPVs. Notably, the widespread use of the highly sensitive NAAT and its relatively lower clinical specificity have led to overdiagnosis of C. difficile by identifying carriers when NAAT is used as the sole diagnostic method. Overdiagnosis of C. difficile has resulted in unwarranted treatment, possibly attributing to resistance to metronidazole and vancomycin, increased risk for overgrowth of vancomycin-resistant enterococci strains in stool specimens, and increased hospitalization thereby impacting patient safety and healthcare costs. Strategies to optimize the clinical sensitivity and specificity of current laboratory tests are critical to differentiate the clinical CDI from colonization. To achieve high diagnostic yield, if preagreed institutional criteria for stool submission are not used, a multistep approach to CDI diagnosis is recommended, such as either GDH or NAAT followed by toxins A/B EIA in conjunction with laboratory stewardship by evaluating C. difficile test orders for appropriateness and providing feedback. Furthermore, antimicrobial stewardship, along with provider education on appropriate testing for C. difficile, is vital to differentiate CDI from colonization. Springer Healthcare 2021-03-26 2021-06 /pmc/articles/PMC8116462/ /pubmed/33770398 http://dx.doi.org/10.1007/s40121-021-00417-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Lee, Helen S. Plechot, Kamryn Gohil, Shruti Le, Jennifer Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis |
title | Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis |
title_full | Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis |
title_fullStr | Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis |
title_full_unstemmed | Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis |
title_short | Clostridium difficile: Diagnosis and the Consequence of Over Diagnosis |
title_sort | clostridium difficile: diagnosis and the consequence of over diagnosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116462/ https://www.ncbi.nlm.nih.gov/pubmed/33770398 http://dx.doi.org/10.1007/s40121-021-00417-7 |
work_keys_str_mv | AT leehelens clostridiumdifficilediagnosisandtheconsequenceofoverdiagnosis AT plechotkamryn clostridiumdifficilediagnosisandtheconsequenceofoverdiagnosis AT gohilshruti clostridiumdifficilediagnosisandtheconsequenceofoverdiagnosis AT lejennifer clostridiumdifficilediagnosisandtheconsequenceofoverdiagnosis |